Evaluation of effects of melatonin and caffeic acid phenethyl ester on acute potassium dichromate toxicity and genotoxicity in rats

Cengiz, Müjgan; Alansal, Nurnisa Oya; Tunçdemi̇r, Matem; Tanrıverdi, Gamze; Bayoğlu, Burcu

doi:10.4103/0253-7613.186213

Cited by 11 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [ 121 ] GT In vivo study in rats or mice 4–10 mg/kg i.p. Protective effects against genotoxic action of potassium dichromate, cobalt, ethanol, paraquat [ [122] , [123] , [124] , [125] ] GT In vitro study using human lymphocytes 0.2 mM Anti-genotoxic effect on mercuric chloride and gossypol [ 110 , 126 ] CG Transgenic mice at increased risk for prostate adenocarcinoma 10–20 mcg/L in dw 18 weeks Strong prostate cancer inhibitory effect [ 127 ] CG Transgenic mice susceptible for mammary tumours 50–200 mcg/kg per day via gavage 30 weeks Reduced incidence and growth rate of mammary tumours [ 128 , 144 ] CG Rats, mice susceptible for breast cancer 10–20 mcg/L in dw >1 yr No induction of uterine tumours, lower incidence of mammary tumours. [ 129 , 130 ] …”

Section: Safety Of Melatonin Administrationmentioning

confidence: 99%

“…A full range of genotoxicity tests, including in vitro non-mammalian [ 113 , [116] , [117] , [118] ] and in vitro mammalian cell systems [ 113 , 117 , 119 ], and in vivo mammalian system [ 120 , 121 ] tests consistently found no evidence that melatonin is genotoxic (neither mutagenic or clastogenic). Furthermore, several studies in various in vitro/in vivo systems have reported the anti-genotoxic action of melatonin [ [122] , [123] , [124] , [125] , [126] ], usually ascribed to its antioxidant activity.…”

Section: Safety Of Melatonin Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of supplemental melatonin for delayed sleep–wake phase disorder in children: an overview

et al. 2020

View full text Add to dashboard Cite

Delayed sleep–wake phase disorder (DSPD) is the most frequently occurring intrinsic circadian rhythm sleep–wake disorder, with the highest prevalence in adolescence. Melatonin is the first-choice drug treatment. However, to date melatonin (in a controlled-release formulation) is only authorised for the treatment of insomnia in children with autism or Smiths-Magenis syndrome. Concerns have been raised with respect to the safety and efficacy of melatonin for more general use in children, as melatonin has not undergone the formal safety testing required for a new drug, especially long-term safety in children. Melatonin is known to have profound effects on the reproductive systems of rodents, sheep and primates, as well as effects on the cardiovascular, immune and metabolic systems. The objective of the present article was therefore to establish the efficacy and safety of exogenous melatonin for use in children with DSPD, based on in vitro, animal model and clinical studies by reviewing the relevant literature in the Medline database using PubMed. Acute toxicity studies in rats and mice showed toxic effects only at extremely high melatonin doses (>400 mg/kg), some tens of thousands of times more than the recommended dose of 3–6 mg in a person weighing 70 kg. Longer-term administration of melatonin improved the general health and survival of ageing rats or mice. A full range of in vitro/in vivo genotoxicity tests consistently found no evidence that melatonin is genotoxic. Similarly long term administration of melatonin in rats or mice did not have carcinogenic effects, or negative effects on cardiovascular, endocrine and reproductive systems. With regard to clinical studies, in 19 randomised controlled trials comprising 841 children and adolescents with DSPD, melatonin treatment (usually of 4 weeks duration) consistently improved sleep latency by 22–60 min, without any serious adverse effects. Similarly, 17 randomised controlled trials, comprising 1374 children and adolescents, supplementing melatonin for indications other than DSPD, reported no relevant adverse effects. In addition, 4 long-term safety studies (1.0–10.8 yr) supplementing exogenous melatonin found no substantial deviation of the development of children with respect to sleep quality, puberty development and mental health scores. Finally, post-marketing data for an immediate-release melatonin formulation (Bio-melatonin), used in the UK since 2008 as an unlicensed medicine for sleep disturbance in children, recorded no adverse events to date on sales of approximately 600,000 packs, equivalent to some 35 million individual 3 mg tablet doses (MHRA yellow card adverse event recording scheme). In conclusion, evidence has been provided that melatonin is an efficacious and safe chronobiotic drug for the treatment of DSPD in children, provided that it is administered at the correct time (3–5 h before endogenous melatonin starts to rise in dim light (DLMO)), and in the correct (minimal effective) dose. As the stat...

show abstract

Section: Safety Of Melatonin Administrationmentioning

confidence: 99%

Section: Safety Of Melatonin Administrationmentioning

confidence: 99%

Efficacy and safety of supplemental melatonin for delayed sleep–wake phase disorder in children: an overview

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[ 1 ] Cr occurs in several states at oxidation, ranging from +2 to +6. [ 2 ] However, it is unstable except +3 and +6 forms in nature. [ 3 ] Studies have shown that Cr 6+ can affect human health, Cr 3+ is a beneficial micronutrient.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and bioavailability of chromium malate and its influence on trace metals absorption after oral or intravenous administration

Feng

Wang

et al. 2018

Indian J Pharmacol

View full text Add to dashboard Cite

OBJECTIVES:In our preliminary study, chromium malate could decrease the blood glucose level in mice with diabetes and exhibits good benefits in treating glycometabolism and adipose metabolization obstacle in rats with type 2 diabetes. This study was aimed at assessing the pharmacokinetics and bioavailability of chromium malate and influence on trace metals absorption in rats.METHODS:BAPP 2.3 pharmacokinetic calculating program (China Pharmaceutical University Medicine Center) was used to calculate the pharmacokinetic parameters. Models of type 2 diabetic mellitus rats were applied to analyzed Ca, Mg, Fe, Cu, and Zn contents.RESULTS:The results showed that mean retention time (MRT) in chromium malate group was significantly prolonged and the area under the curve (AUC) and relative bioavailability of chromium malate (male) group were significant increase compared to chromium picolinate group. The serum Ca, Mg, Fe, Cu, and Zn contents in chromium malate (at doses of 15 and 20 μg Cr/kg bw) groups were significantly increased compared to control group, chromium trichloride group, and chromium picolinate group in type 2 diabetes mellitus rats.CONCLUSIONS:Those results indicated that chromium malate can significantly prolong MRT and increase AUC (male). Moreover, chromium malate is more effective at treating increased serum Ca, Mg, Fe, Cu, and Zn contents compared to chromium trichloride and chromium picolinate.

show abstract

Chlorogenic acid mitigates potassium dichromate-induced acute hepato-nephrotoxicity by attenuating the NF-κB signalling pathway

Orhan,

Turkmen,

Demirel

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

Evaluation of effects of melatonin and caffeic acid phenethyl ester on acute potassium dichromate toxicity and genotoxicity in rats

Cited by 11 publications

References 25 publications

Efficacy and safety of supplemental melatonin for delayed sleep–wake phase disorder in children: an overview

Efficacy and safety of supplemental melatonin for delayed sleep–wake phase disorder in children: an overview

Pharmacokinetics and bioavailability of chromium malate and its influence on trace metals absorption after oral or intravenous administration

Chlorogenic acid mitigates potassium dichromate-induced acute hepato-nephrotoxicity by attenuating the NF-κB signalling pathway

Contact Info

Product

Resources

About